Stocks
ResMed Financial Statements (RMD) |
||||||||||
| ResMedsmart-lab.ru | % | 2021 | 2022 | 2023 | 2023 | LTM ? | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 19.08.2021 | 30.06.2022 | 12.08.2022 | 30.06.2023 | 11.08.2023 | 26.04.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 3 197 | 3 578 | 4 223 | 4 223 | 4 720 | ||||
| Operating Income, bln rub | 903.7 | 1 000 | 1 132 | 1 132 | 1 299 | |||||
| EBITDA, bln rub | ? | 1 099 | 1 194 | 1 340 | 1 340 | 1 536 | ||||
| Net profit, bln rub | ? | 474.5 | 779.4 | 897.6 | 897.6 | 1 019 | ||||
| OCF, bln rub | ? | 736.7 | 351.1 | 693.3 | 693.3 | 947.7 | ||||
| CAPEX, bln rub | ? | 116.8 | 156.0 | 134.0 | 134.0 | 71.0 | ||||
| FCF, bln rub | ? | 619.9 | 195.1 | 559.3 | 559.3 | 876.7 | ||||
| Dividend payout, bln rub | 226.7 | 245.3 | 258.3 | 258.3 | 211.8 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 47.8% | 31.5% | 28.8% | 28.8% | 20.8% | |||||
| OPEX, bln rub | 926.7 | 1 024 | 1 204 | 1 204 | 1 305 | |||||
| Cost of production, bln rub | 1 358 | 1 554 | 1 867 | 1 867 | 2 051 | |||||
| R&D, bln rub | 225.3 | 253.6 | 287.6 | 287.6 | 301.9 | |||||
| Interest expenses, bln rub | 24.0 | 22.3 | 47.4 | 47.4 | 49.7 | |||||
| Assets, bln rub | 4 728 | 5.10 | 5 096 | 6 752 | 6 752 | 6 815 | ||||
| Net Assets, bln rub | ? | 2 886 | 3.36 | 3 361 | 4 130 | 4 130 | 4 630 | |||
| Debt, bln rub | 793.7 | 0.918 | 917.6 | 1 580 | 1 580 | 1 167 | ||||
| Cash, bln rub | 295.3 | 0.274 | 273.7 | 227.9 | 227.9 | 237.9 | ||||
| Net debt, bln rub | 498.4 | 0.64 | 643.8 | 1 352 | 1 352 | 929.5 | ||||
| Ordinary share price, rub | 246.5 | 209.6 | 209.6 | 218.5 | 218.5 | 150.1 | ||||
| Number of ordinary shares, mln | 145.3 | 146.1 | 0.000 | 146.8 | 147.0 | |||||
| Market cap, bln rub | 35 823 | 0 | 30 620 | 0 | 32 068 | 22 061 | ||||
| EV, bln rub | ? | 36 321 | 1 | 31 264 | 1 352 | 33 420 | 22 991 | |||
| Book value, bln rub | 565 | 3 | 1 078 | 4 130 | 807 | 1 293 | ||||
| EPS, rub | ? | 3.27 | 5.34 | 6.12 | 6.93 | |||||
| FCF/share, rub | 4.27 | 1.34 | 3.81 | 5.97 | ||||||
| BV/share, rub | 3.89 | 7.38 | 5.50 | 8.80 | ||||||
| EBITDA margin, % | ? | 34.4% | 33.4% | 31.7% | 31.7% | 32.5% | ||||
| Net margin, % | ? | 14.8% | 21.8% | 21.3% | 21.3% | 21.6% | ||||
| FCF yield, % | ? | 1.73% | 0.00% | 0.64% | 0.00% | 1.74% | 3.97% | |||
| ROE, % | ? | 16.4% | 0.00% | 23.2% | 21.7% | 21.7% | 22.0% | |||
| ROA, % | ? | 10.0% | 0.00% | 15.3% | 13.3% | 13.3% | 14.9% | |||
| P/E | ? | 75.5 | 39.3 | 0.00 | 35.7 | 21.7 | ||||
| P/FCF | 57.8 | 156.9 | 0.00 | 57.3 | 25.2 | |||||
| P/S | ? | 11.2 | 8.56 | 0.00 | 7.59 | 4.67 | ||||
| P/BV | ? | 63.4 | 0.00 | 28.4 | 0.00 | 39.7 | 17.1 | |||
| EV/EBITDA | ? | 33.0 | 26.2 | 1.01 | 24.9 | 15.0 | ||||
| Debt/EBITDA | 0.45 | 0.54 | 1.01 | 1.01 | 0.61 | |||||
| R&D/CAPEX, % | 192.8% | 162.5% | 214.7% | 214.7% | 425.1% | |||||
| CAPEX/Revenue, % | 3.65% | 4.36% | 3.17% | 3.17% | 1.50% | |||||
| ResMed shareholders | ||||||||||
